Kymera Therapeutics (KYMR)
(Real Time Quote from BATS)
$49.57 USD
-0.18 (-0.36%)
Updated Aug 27, 2024 10:10 AM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Company Summary
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade the disease-causing proteins by harnessing the body’s own natural protein degradation system.
The company has a proprietary targeted protein degradation (TPD) platform, known as Pegasus, which it has utilized to design novel protein degraders focused in the areas of immunology-inflammation and oncology. The immunology programs are IRAK4, STAT6 and TYK2. The oncology pipeline includes STAT3 and MDM2. Among these, current clinical-stage programs are IRAK4, STAT3 and MDM2, which address high-impact targets within biologically-proven pathways, providing ...
Company Summary
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade the disease-causing proteins by harnessing the body’s own natural protein degradation system.
The company has a proprietary targeted protein degradation (TPD) platform, known as Pegasus, which it has utilized to design novel protein degraders focused in the areas of immunology-inflammation and oncology. The immunology programs are IRAK4, STAT6 and TYK2. The oncology pipeline includes STAT3 and MDM2. Among these, current clinical-stage programs are IRAK4, STAT3 and MDM2, which address high-impact targets within biologically-proven pathways, providing the opportunity to treat a broad range of immuno-inflammatory diseases, hematologic malignancies and/or solid tumors.
Kymera has collaborated with Sanofi on the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology. The company’s disclosed preclinical programs target STAT6 and TYK2, two proteins in well-validated pathways. Both programs are currently in INDenabling studies.
In May 2019, Kymera entered into a collaboration agreement with Vertex Pharmaceuticals to advance small molecule protein degradation against up to six targets. The agreement granted Vertex the exclusive option to license the rights to the product candidates developed through the collaboration. Kymera was responsible for the discovery and preclinical research on the targets. Vertex was accountable for the development, manufacturing, and commercialization of the product candidates after it exercised its option to license. Vertex paid a non-refundable upfront payment of $50.0 million and purchased 3,059,695 shares of the company’s series B-1 convertible preferred stock at $6.54 per share.
The company does not have an approved drug yet and hence does not earn any drug sales. Presently, it only earns collaboration revenues from Sanofi. The collaboration with Vertex expired upon the completion of the initial research term on May 9, 2023.
The company generated collaboration revenues of $78.6 million in 2023, up from $46.8 million in 2022.
General Information
Kymera Therapeutics, Inc
500 North Beacon Street 4th Floor
Watertown, MA 02472
Phone: 857-285-5300
Fax: NA
Email: investors@kymeratx.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/7/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.83 |
Current Year EPS Consensus Estimate | -2.86 |
Estimated Long-Term EPS Growth Rate | 10.50 |
Exp Earnings Date | 11/7/2024 |
Price and Volume Information
Zacks Rank | ![]() |
Yesterday's Close | 49.75 |
52 Week High | 50.19 |
52 Week Low | 9.60 |
Beta | 2.22 |
20 Day Moving Average | 482,141.41 |
Target Price Consensus | 52.43 |
4 Week | 14.00 |
12 Week | 57.64 |
YTD | 95.40 |
4 Week | 10.89 |
12 Week | 48.28 |
YTD | 65.94 |
Shares Outstanding (millions) | 61.75 |
Market Capitalization (millions) | 3,072.22 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | 13.43% |
vs. Previous Quarter | 15.94% |
vs. Previous Year | 55.33% |
vs. Previous Quarter | 149.34% |
Price/Book | 4.46 |
Price/Cash Flow | NA |
Price / Sales | 34.70 |
6/30/24 | -28.88 |
3/31/24 | -31.92 |
12/31/23 | -34.83 |
6/30/24 | -22.37 |
3/31/24 | -23.98 |
12/31/23 | -25.30 |
6/30/24 | 8.45 |
3/31/24 | 9.57 |
12/31/23 | 4.73 |
6/30/24 | 8.45 |
3/31/24 | 9.57 |
12/31/23 | 4.73 |
6/30/24 | -178.27 |
3/31/24 | -194.67 |
12/31/23 | -187.00 |
6/30/24 | -178.27 |
3/31/24 | -194.67 |
12/31/23 | -187.00 |
6/30/24 | -178.27 |
3/31/24 | -194.67 |
12/31/23 | -186.99 |
6/30/24 | 11.16 |
3/31/24 | 11.59 |
12/31/23 | 7.12 |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |
6/30/24 | 0.14 |
3/31/24 | 0.16 |
12/31/23 | 0.33 |